Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price rose 30% on Tuesday . The stock traded as high as C$0.15 and last traded at C$0.13. Approximately 430,289 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 480,285 shares. The stock had previously closed at C$0.10.
Hemostemix Price Performance
The company has a 50 day moving average of C$0.10 and a two-hundred day moving average of C$0.14. The firm has a market cap of C$18.94 million, a P/E ratio of -3.79 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
Insiders Place Their Bets
In other Hemostemix news, Director Peter Alan Lacey purchased 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is owned by company insiders.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Health Care Stocks Explained: Why You Might Want to Invest
- Top 5 Stocks Hedge Funds Are Buying Right Now
- The Most Important Warren Buffett Stock for Investors: His Own
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- What Are Dividend Achievers? An Introduction
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
